Utah spine center selected for 2-level degenerative disc disease study

Alan Condon -   Print  |

Implant manufacturer Centinel Spine has named Masson Spine Institute in Park City, Utah, as an investigational site for a two-level clinical trial investigating the treatment of symptomatic cervical disc disease.

The study will examine the safety and efficacy of Prodisc C in cervical disc injury, according to a December news release.

The trial aims to demonstrate that Prodisc C SK and Prodisc C Vivo are at least as safe and effective as Mobi-C — a similar cervical disc prosthesis on the market — to treat symptomatic cervical disc disease at two contiguous levels from C3 to C7.

Masson Spine Institute is now enrolling patients in the clinical trial.

More articles on practice management:
How CMS' changes will affect spine surgeons in 2021 — Prior authorization, fee cuts & more
Former orthopedic practice owner gets 5 years in prison for illegally prescribing opioids
Surgeons' brand exceeds patient outcomes — How you should build your practice's brand

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers